NovaBridge Reports Promising 2025 Results, Advances Blockbuster Drug Candidates

Biotech platform company highlights positive data for gastric cancer and wet AMD programs, plans next-stage studies in 2026.

Apr. 8, 2026 at 6:05am

Got story updates? Submit your updates here. ›

A minimalist, photorealistic studio still life featuring a collection of polished, geometric objects arranged elegantly on a clean, monochromatic background, conceptually representing the strategic progress and financial strength of the biotech company NovaBridge.NovaBridge's strategic transformation and promising drug pipeline signal a new era of innovation in the biotech industry.Rockville Today

NovaBridge Biosciences, a global biotechnology platform company, announced strong financial results for 2025 and provided updates on the progress of its two lead investigational programs, givastomig for gastric cancer and VIS-101 for wet age-related macular degeneration (wet AMD). The company reported compelling proof-of-concept data for both potential best-in-class/first-in-class assets, reinforcing their class-leading potential and de-risking their clinical paths forward.

Why it matters

NovaBridge's transformation into a global biotech platform with a focus on high-value therapeutic assets represents a strategic shift that appears to be paying off. The positive data for givastomig and VIS-101 validate the company's approach and position it for potential near-term regulatory milestones and commercialization, which could significantly impact the treatment landscape for gastric cancer and wet AMD patients.

The details

For givastomig, NovaBridge reported a 75% objective response rate in its Phase 1b dose expansion study, with durable responses and good overall tolerability. The FDA also confirmed the program's potential eligibility for an Accelerated Approval Pathway. Meanwhile, VIS-101 demonstrated rapid, robust, and durable treatment responses in its successful Phase 2a readout for wet AMD, positioning it as a potential best-in-class VEGF-A x ANG-2 inhibitor. NovaBridge plans to initiate next-stage studies for both programs in 2026, bringing them closer to regulatory approval and patient access.

  • In January 2026, NovaBridge reported positive Phase 1b dose expansion data for givastomig.
  • In March 2026, NovaBridge reported givastomig's potential eligibility for an Accelerated Approval Pathway.
  • In February 2026, Visara reported positive Phase 2a data for VIS-101.

The players

NovaBridge Biosciences

A global biotechnology platform company committed to accelerating access to innovative medicines.

Fu Wei

Executive Chairman of the Board of NovaBridge.

Sean Fu

Chief Executive Officer of NovaBridge.

Visara, Inc.

NovaBridge's majority-owned subsidiary that controls global rights to VIS-101 outside of Greater China and certain other Asian countries.

Emmett T. Cunningham, Jr.

Vice-Chairman of the NovaBridge Board of Directors, and Founder and Executive Chairman of Visara.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a consequential year for NovaBridge, with our successful transformation to a global biotech platform. The accelerated momentum that we have experienced over the last quarter – marked by compelling proof-of-concept data for our two potential class-leading, blockbuster product candidates, givastomig and VIS-101 -- serves as strong validation of our strategy.”

— Fu Wei, Executive Chairman of the Board of NovaBridge

“Compelling clinical results from the last quarter have reinforced the class-leading potential for givastomig and VIS-101 and meaningfully de-risked their clinical paths forward. For givastomig, the FDA confirmed potential eligibility for an Accelerated Approval pathway at a productive Type B meeting, following robust potential best-in-class Phase 1b efficacy and favorable overall tolerability results. At the same time, VIS-101 continues to advance in wet AMD following its successful Phase 2a readout showing rapid, robust, durable and potential best-in-class responses.”

— Sean Fu, Chief Executive Officer of NovaBridge

What’s next

NovaBridge plans to initiate a registrational Phase 3 trial for givastomig under the Accelerated Approval Pathway as early as the end of 2026. The company also expects to begin a Phase 2b study for VIS-101 in wet AMD in the second half of 2026, followed by the initiation of a global Phase 3 program in 2027.

The takeaway

NovaBridge's transformation into a global biotech platform has enabled the rapid advancement of its promising drug candidates, givastomig and VIS-101, which have demonstrated compelling proof-of-concept data and the potential to become best-in-class/first-in-class treatments for gastric cancer and wet AMD, respectively. The company's strategic focus and execution have positioned it for potential near-term regulatory milestones and commercialization, which could significantly impact the treatment landscape for patients in need.